美国 · SEC FORM 4
Janux Therapeutics, Inc.
JANX · Nasdaq · CIK 0001817713 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
11 同一窗口内观察到的 Form 4 交易行
2 sales · 9 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-03-07 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. · $3.4M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出较低
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Campbell David AlanPresident and CEO
○○
Simson JakeDirector
○
Kung WinstonDirector
○
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M.Director; Director,TenPercentOwner
○
Hernday NatashaDirector
○
DOBMEIER ERICDirector
○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 4 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-03-07 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M..
近期 Form 4 活动
0买入
12卖出
20其他 Form 4 交易行
22SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出2 sale line(s) · 仅供背景
其他9 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 5,684,346
- 上期报告
- 5,891,965
- 日均成交量
- 969,533
- 回补天数
- 5.9
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-03-07 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 110,206 | USD 31.02 | USD 3,418,590 | SEC 申报 ↗ |
| 2025-03-06 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 372,093 | USD 30.78 | USD 11,453,023 | SEC 申报 ↗ |
| 2025-03-05 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 341,742 | USD 30.64 | USD 10,471,352 | SEC 申报 ↗ |
| 2024-10-18 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 1,200,000 | USD 44.75 | USD 53,700,000 | SEC 申报 ↗ |
| 2023-11-13 | Reardon Tighe | 买入 (P) | Common Stock | 849,854 | USD 5.87 | USD 4,988,643 | SEC 申报 ↗ |
| 2023-11-13 | Lichter Jay | 买入 (P) | Common Stock | 849,854 | USD 5.87 | USD 4,988,643 | SEC 申报 ↗ |
| 2023-11-13 | Avalon BioVentures I, LP; Avalon BioVentures SPV I, L.P.; Avalon Ventures XI, L.P. | 买入 (P) | Common Stock | 849,854 | USD 5.87 | USD 4,988,643 | SEC 申报 ↗ |
| 2023-07-19 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 买入 (P) | Common Stock | 495,008 | USD 12.46 | USD 6,167,800 | SEC 申报 ↗ |
| 2021-06-15 | Thompson Peter A. | 买入 (P) | Common Stock | 705,853 | USD 17.00 | USD 11,999,501 | SEC 申报 ↗ |
| 2021-06-15 | Reardon Tighe | 买入 (P) | Common Stock | 629,411 | USD 17.00 | USD 10,699,987 | SEC 申报 ↗ |
| 2021-06-15 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 705,853 | USD 17.00 | USD 11,999,501 | SEC 申报 ↗ |
| 2021-06-15 | Lichter Jay | 买入 (P) | Common Stock | 629,411 | USD 17.00 | USD 10,699,987 | SEC 申报 ↗ |
| 2021-06-15 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Common Stock | 2,941,176 | USD 17.00 | USD 49,999,992 | SEC 申报 ↗ |
| 2021-06-15 | Bregua Corp | 买入 (P) | Common Stock | 58,823 | USD 17.00 | USD 999,991 | SEC 申报 ↗ |
| 2021-06-15 | Avalon BioVentures SPV I, L.P.; Avalon Ventures XI, L.P. | 买入 (P) | Common Stock | 629,411 | USD 17.00 | USD 10,699,987 | SEC 申报 ↗ |
Form 4 申报证据
32 transaction lines in the latest 365-day window; 240 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | Campbell David Alan | 赠与 (G) | Common Stock | 123,840 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-08 | Campbell David Alan | 期权行权／转换 (M) | Common Stock | 7,000 | USD 4.21 | USD 29,470 | SEC 申报 ↗ |
| 2026-06-11 | Simson Jake | 奖励／授予 (A) | Common Stock | 5,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | Campbell David Alan | 赠与 (G) | Common Stock | 123,840 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-08 | Campbell David Alan | 期权行权／转换 (M) | Common Stock | 7,000 | USD 4.21 | USD 29,470 | SEC 申报 ↗ |
| 2026-06-11 | Simson Jake | 奖励／授予 (A) | Common Stock | 5,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-11 | Kung Winston | 奖励／授予 (A) | Common Stock | 5,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-11 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M. | 奖励／授予 (A) | Common Stock | 5,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-11 | Hernday Natasha | 奖励／授予 (A) | Common Stock | 5,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-11 | DOBMEIER ERIC | 奖励／授予 (A) | Common Stock | 5,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-11 | CAPPS VICKIE L | 奖励／授予 (A) | Common Stock | 5,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-11 | Barrett Ronald W | 奖励／授予 (A) | Common Stock | 5,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-02 | Doyle Janeen Noel | 卖出 (S) | Common Stock | 4,059 | USD 14.03 | USD 56,948 | SEC 申报 ↗ |
| 2026-05-11 | Dobek Maria | 卖出 (S) | Common Stock | 2,038 | USD 14.17 | USD 28,878 | SEC 申报 ↗ |
| 2026-02-02 | Go William | 奖励／授予 (A) | Common Stock | 44,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | Winter Charles M. | 卖出 (S) | Common Stock | 2,401 | USD 13.73 | USD 32,966 | SEC 申报 ↗ |
| 2026-01-02 | Winter Charles M. | 奖励／授予 (A) | Common Stock | 28,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | Meyer Andrew Hollman | 卖出 (S) | Common Stock | 1,879 | USD 13.73 | USD 25,799 | SEC 申报 ↗ |
| 2026-01-02 | McIver Zachariah | 卖出 (S) | Common Stock | 2,714 | USD 13.73 | USD 37,263 | SEC 申报 ↗ |
| 2026-01-02 | McIver Zachariah | 奖励／授予 (A) | Common Stock | 29,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | Doyle Janeen Noel | 奖励／授予 (A) | Common Stock | 36,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | Dobek Maria | 卖出 (S) | Common Stock | 1,462 | USD 13.73 | USD 20,073 | SEC 申报 ↗ |
| 2026-01-02 | Dobek Maria | 奖励／授予 (A) | Common Stock | 18,935 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | DiRaimondo Thomas | 卖出 (S) | Common Stock | 2,505 | USD 13.73 | USD 34,394 | SEC 申报 ↗ |
| 2026-01-02 | DiRaimondo Thomas | 奖励／授予 (A) | Common Stock | 31,400 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | Campbell David Alan | 卖出 (S) | Common Stock | 8,072 | USD 13.73 | USD 110,829 | SEC 申报 ↗ |
| 2026-01-02 | Campbell David Alan | 奖励／授予 (A) | Common Stock | 96,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-01 | Meyer Andrew Hollman | 卖出 (S) | Common Stock | 3,333 | USD 32.98 | USD 109,913 | SEC 申报 ↗ |
| 2025-12-01 | Meyer Andrew Hollman | 期权行权／转换 (M) | Common Stock | 3,333 | USD 10.59 | USD 35,296 | SEC 申报 ↗ |
| 2025-11-14 | Meyer Andrew Hollman | 卖出 (S) | Common Stock | 3,333 | USD 30.00 | USD 99,990 | SEC 申报 ↗ |
| 2025-11-14 | Meyer Andrew Hollman | 期权行权／转换 (M) | Common Stock | 3,333 | USD 10.59 | USD 35,296 | SEC 申报 ↗ |
| 2025-10-28 | Meyer Andrew Hollman | 卖出 (S) | Common Stock | 16,665 | USD 30.06 | USD 500,950 | SEC 申报 ↗ |
| 2025-10-28 | Meyer Andrew Hollman | 期权行权／转换 (M) | Common Stock | 16,665 | USD 6.76 | USD 112,689 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | JANX |
| CIK | 0001817713 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 240 transaction lines from 2021-06-15 to 2026-07-31 19 P purchase lines · 103 S sale lines · 118 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.